Cytokines are critical in linking the innate and adaptive immune responses to bacterial, fungal, and parasitic infection

Advances in Internal Medicine

Volumn 44, Issue , 1999, Pages 353-388

  Seder, Robert A ^a   Gazzinelli, Ricardo T ^b,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12;

ANIMAL; BACTERIAL INFECTION; CELLULAR IMMUNITY; HISTOPLASMOSIS; HUMAN; IMMUNOLOGY; LISTERIA MONOCYTOGENES; LISTERIOSIS; MACROPHAGE; MYCOSIS; NATURAL KILLER CELL; NEUTROPHIL; PARASITOSIS; REVIEW; T LYMPHOCYTE; TOXOPLASMOSIS;

ANIMALS; BACTERIAL INFECTIONS; CYTOKINES; HISTOPLASMOSIS; HUMANS; IMMUNITY, CELLULAR; INTERFERON TYPE II; INTERLEUKIN-12; KILLER CELLS, NATURAL; LISTERIA INFECTIONS; LISTERIA MONOCYTOGENES; MACROPHAGES; MYCOSES; NEUTROPHILS; PARASITIC DISEASES; T-LYMPHOCYTES; TOXOPLASMOSIS;

EID: 0032611410     PISSN: 00652822     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (163)

1. Kaufman SH: Immunity to intracellular bacteria. Annu Rev Immunol 11:129-163, 1993.
2. Unanue ER: Studies in listeriosis show the strong symbiosis between the innate cellular system and the T-cell response. Immunol Rev 158:11-25, 1997.
3. Tripp CS, Wolf SF, Unanue ER: Interleukin 12 and tumor necrosis factor a are costimulators of interferon -y production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc NatI Acad Sei USA 90:3725-3729, 1993.
4. Tripp CS, Gately MK, Hakimin J, et al: Neutralization of IL-12 decreases resistance to Listeria in SCID and C.B.-17 mice: Reversal by IFN-y. f Immunol 152:1883-1887, 1994.
5. Wagner RD, Steinberg H, Brown JF, et al: Recombinant interleukin 12 enhances resistance of mice to Listeria monocytogenes infection. Microb Pathog 17:175-186, 1994.
6. Hsieh CS, Macatonia SE, Tripp CS, et al: Development of TH1 CD4+ T cells through IL-12 produced by L/steria-induced macrophages. Science 260:547-549, 1993.
7. Bancroft GJ, Sheehan KCF, Schreiber RD, et al: Tumor necrosis factor is involved in the T cell independent pathway of macrophage activation in SCID mice. J Immunol 143:127-130, 1989.
8. Havell EA: Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol 143:2894-2899, 1989.
9. Pfeffer K, Matsuyama T, Kundig TM, et al: Mice deficient for the 55 kD tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to I. monocytogenes. Cell 73:457-467, 1993.
10. Rothe J, Lesslauer W, Lotscher H, et al: Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364:798-802, 1994.
11. Erickson SL, deSauvage FJ, Kikly K, et al: Decreased sensitivity to tumor-necrosis factor but normal T-cell development in TNF-receptor2-deficient mice. Nature 372:560-563, 1994.
12. Wherry JC, Schreiber RD, Unanue ER: Regulation of -y Interferon production by natural killer cells in SCID mice: Roles of tumor necrosis factor and bacterial stimuli. Infect Immun 59:1709-1715, 1991.
13. Kopf M, Baumann H, Freer G, et al: Impaired immune and acute phase responses in interleukin-6 deficient mice. Nature 368:339-342, 1994.
14. Dalrymple SA, Lucian LA, Slattery R, et al: Interleukin-6 deficient mice are highly susceptible to Listeria monocytogenes infection: Correlation with inefficient neutrophilia. Infect Immun 63:2262-2268, 1995.
15. Tanaka T, Akira S, Yoshida K, et al: Targeted disruption of the NKIL-6 gene discloses its essential role in bacterial killing and tumor cytotoxicity by macrophages. Cell 80:353-361, 1995.
16. Rogers HW, Sheehan KCF, Brunt LM, et al: Interleukin-1 participates in the development of anti-Listeria responses in normal and SCID mice. Proc Natl Acad Sei USA 89:1011-1015, 1992.
17. Rogers HW, Tripp CS, Schreiber RD, et al: Endogenous IL-1 is required for neutrophil recruitment and macrophage activation during murine listeriosis. J Immunol 153:2093-2101, 1994.
18. Havell EA, Moldawer LL, Helfgott D, et al: Type 1 IL-1 receptor blockade exacerbates murine listeriosis. J Immunol 148:1486-1492, 1992.
19. Hunter ÇA, Chizzonite R, Remington JS: IL-1β is required for IL-12 to induce production of IFN-/ by NK cells. A role for IL-lβ in the T cell-independent mechanism of resistance against intracellular pathogens. J Immunol 154:4347-4354, 1995.
20. MacMicking JD, Nathan C, Horn G, et al: Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 81:641-650, 1995.
21. Flesch IE, Kaufmann SHE: Role of macrophages and aβ T lymphocytes in early interleukin 10 production during Listeria monocytogenes infection. Int Immunol 6:463-469, 1994.
22. Kelly JP, Bancroft GJ: Administration of interleukin-10 abolishes innate resistance to Listeria monocytogenes. Eurf Immunol 26:356-364, 1996.
23. Wagner RD, Maroushek NM, Brown }F, et al: Treatment with anti-interleukin 10 monoclonal antibody enhances early resistance to but im-pairs complete clearance of Listeria monocytogenes infection in mice. Infect Immun 62:2345-2353, 1994.
24. Tripp CS, Beckerman KP, Unanue ER: Immune complexes inhibit antimicrobial responses through IL-10 production: Effect in severe combined immunodeficient mice during Listeria infection. J Clin Invest 95:1628-1634, 1995.
25. Dai WD, Kohler G, Brombacher F: Both innate and acquired immunity to Listeria monocytogenes infection are increased in IL-10 deficient mice. J Immunol 158:5297-5304, 1997.
26. Bancroft GJ, Schreiber RD, Unanue ER: Natural immunity: A T-cellindependent pathway of macrophage activation, denned in the seid mouse. Immunol Rev 124:5-24, 1991.
27. Conlan E.W, North RJ: Neutrophil-mediated dissolution of infected host cells as a defense strategy against a facultative intracellular bacterium. J Exp Med 174:741-744, 1991.
28. Conlan JW, Dunn PL, North RJ: Leukocyte-mediated lysis of infected hepatocytes during listeriosis occurs in mice depleted of NK cells and CD4+CD8+Thyl.2 + T cells. Infect Immun 61:2703-2712, 1993.
29. Czuprynski CJ, Henson PM, Campbell PA: Killing of Listeria monocytogenes by inflammatory neutrophils and mononuclear phagocytes from immune and nonimmune mice. /Leukoc Biol 35:193-208, 1984.
30. Alford CE, Amaral E, Campbell PA: Listericidal activity of human neutrophil cathepsin G. J Gen Microbiol 136:997-1000, 1990.
31. Czuprynski CJ, Brown JF, Wagner RD, et al: Administration of antigranulocyte monoclonal antibody RB6-8C5 prevents expression of acquired resistance to Listeria monocytogenes infection in previously immunized mice. Infect Immun 83:302-307, 1994.
32. Rogers HW, Unanue ER: Neutrophils are involved in acute, nonspecific resistance to Listeria monocytogenes in mice. Infect Immun 61:5090-5096, 1993.
33. Conlan JW, North RJ: Neutrophils are essential for early anti-Listeria defense in the liver, but not in the spleen or peritoneal cavity, as revealed by a granulocyte-depleting monoclonal antibody. J Exp Med 179:259-268, 1994.
34. Buchmier NA, Schreiber RD: Requirement of endogenous interferon-y production for resolution of Listeria monocytogenes. Proc Natl Acad Sei USA 82:7404-7408, 1985.
35. Dalton DK, Pitts MS, Keshav S, et al: Multiple defects of immune cell function in mice with disrupted interferon-y genes. Science 259:1739-1742, 1993.
36. Harty JT, Bevan MJ: Specific immunity to Listeria monocytogenes in the absence of IFN y. Immunity 3:109-117, 1995.
37. Huang S, Hendricks W, Althage A, et al: Immune response in mice that lack the interferon-y-receptor. Science 259:1742-1745, 1993.
38. Meraz MA, White JM, Sheehan KCF, et al: Targeted disruption of the Statl gene in mice reveals unexpected physiologic specificity in the JAK-STAT signalling pathway. Cell 84:431-442, 1996.
39. Zinkernagel RM: Restriction by H-2 gene complex of transfer of cellmediated immunity to Listeria monocytogenes. Nature 251:230-233, 1974.
40. Zinkernagel RM, Althage A, Adler B, et al: H-2 restriction of cell-mediated immunity to intracellular bacterium. J Exp Med 145:1353-1359, 1977.
41. deLibero G, Kaufmann SHE: Antigen-specific Lyt2+ cytolytic T lymphocytes from mice infected with the intracellular bacterium, Listeria monocytogenes. f Immunol 137:2688-2693, 1986.
42. Kaufmann SHE: CD8+ T lymphocytes in intracellular microbial infections. Immunol Today 9:168-171, 1988.
43. Ladel CH, Flesch IE, Arnoldi J, et al: Studies with MHC-deficient knock-out mice reveal impact of both MHC I and MHC II-dependent T cell responses on Listeria monocytogenes infection. J Immunol 153:3116-3122, 1994.
44. Mombaerts P, Arnoldi F, Russ F, et al: Different roles of aβ and -y8 T cells in immunity against an intracellular bacterial pathogen. Nature 365:53-56, 1993.
45. TMpp CS, Kanagawa O, Unanue ER: Secondary response to Listeria infection requires IFN-y but is partially independent of IL-12. J Immunol 155:3427-3432, 1995.
46. Kagi D, Lederman B, Burki K, et al: CD8+ T cell-mediated protection against an intracellular bacterium by perforin-dependent cytotoxicity. Eur J Immunol 24:3068-3072, 1994.
47. White WW, Harty JT: Perforin-deficient CD8+ T cells provide immunity to Listeria monocytogenes by a mechanism that is independent of CD95 and IFN-'y but requires TNF-a. f Immunol 160:898-905, 1998.
48. Schwarz J: Histoplasmosis. New York, Praeger, 1981, pp 198-293.
49. Goodwin RA, Shapiro JL, Thurman GH, et al: Disseminated histoplasmosis. Clinical and pathological correlations. Medicine (Baltimore) 59:1-31, 1980.
50. Johnson PC, Khardori N, Najjar AF, et al: Progressive disseminated histoplasmosis in patients with acquired immunodeficiency syndrome. Am ]Med 85:152-158, 1988.
51. Wheat LJ, Connolly-Stringfield PA, Baker RL, et al: Disseminated histoplasmosis in the acquired immune deficiency syndrome: Clinical finding, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 69:361-374, 1990.
52. Deepe GS Jr, Bullock WE: Histoplasmosis: A granulomatous inflammatory response, in Gallin JI, Goldstein IM, Snyderman R (eds): Inflammation: Basic Principles and Clinical Correlates, ed 2. New York, Raven, 1992, pp 943-948.
53. Cain JA, Deepe GS Jr: Evolution of the primary immune response to Histoplasma capsulatum in murine lung. Infect Immun 66:1473-1481, 1998.
54. Deepe GS Jr, Seder RA: Molecular and cellular determinants of immunity to Histoplasma capsulatum. Res Immunol, in press.
55. Zhou P, Sieve MC, Bennett J, et al: IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN-J. J Immunol 155:785-795, 1995.
56. Allendoerfer R, Boivin GP, Deepe GS Jr: Modulation of immune responses in murine pulmonary histoplasmosis. J Infect Dis 175:905-914, 1997.
57. Zhou P, Miller G, Seder RA: Factors involved in regulating primary and secondary immunity to infection with Histoplasma capsulatum: TNF-a plays a critical role in maintaining secondary immunity in the absence of IFN-y. J Immunol 160:1359-1368, 1998.
58. Allendoerfer R, Deepe GS Jr: Intrapulmonary response to Histoplasma capsulatum in y Interferon knockout mice. Infect Immun 65:2564-2569, 1996.
59. Szalay G, Ladel CH, Blum G, et al: IL-4 neutralization or TNF-a treatment ameliorates disease by an intracellular pathogen in IFN-/ receptor-deficient mice. J Immunol 157:4746-4750, 1996.
60. Smith JG, Magee DM, Williams DM, et al: Tumor necrosis factor-a plays an important role in host defense against Histoplasma capsulatum. J Infect Dis 162:1349-1353, 1990.
61. Wu-Hsieh BA, Lee G-S, Franco M, et al: Early activation of splenic macrophages by tumor necrosis factor ot is important in determining the outcome of experimental histoplasmosis in mice. Infect Immun 60:4230-4238, 1992.
62. Nacy ÇA, Meierovics AI, Belosevic M, et al: TNF-a central regulatory cytokine in the induction of macrophage antimicrobial activities, Pathobiology 59:182-184, 1991.
63. Lane TE, Wu-Hsieh BA, Howard DH: Antihistoplasma effect of activated mouse splenic macrophages involves production of reactive nitrogen intermediates. Infect Immun 62:1940-1945, 1994.
64. Lane TE, Otero GC, Wu-Hsieh BA, et al: Expression of inducible nitric oxide synthase by stimulated macrophages correlates with their antihistoplasma activity. Infect Immun 62:1478-1479, 1994.
65. Zhou P, Sieve MC, Tewari RP, et al: Interleukin-12 modulates the protective immune response to SCID mice infected with Histoplasma capsulatum. Infect Immun 65:936-942, 1997.
66. Patino MM, Williams DM, Ahrens J, et al: Experimental histoplasmosis in the beige mouse. J Leukoc Biol 41:228-235, 1987.
67. Baughman RP, Kim CK, Vinegar A, et al: The pathogenesis of experimental pulmonary histoplasmosis. Correlative studies of histopathology, bronchoalveolar lavage, and respiratory function. Am Rev Respir Dis 134:771-776, 1986.
68. Schnur RA, Newman SL: The respiratory burst response to Histoplasma capsulatum by human neutrophils. Evidence for intracellular trapping of Superoxide anion. J Immunol 144:4765-4772, 1990.
69. Brummer E, Kurita N, Yoshida S, et al: Fungistatic activity of human neutrophils against Histoplasma capsulatum: Correlation with phagocytosis. J Infect Dis 164:158-162, 1991.
70. Newman SL, Gootee L, Gabay JE: Human neutrophil-mediated fungistasis against Histoplasma capsulation: Localization of fungistatic activity to the azurophil granules. J Clin Invest 92:624-663, 1993.
71. Newman SL, Kidd C: Neutrophils are essential in host defense against Histoplasma capsulatum. Presented at the 97th General Meeting of the American Society for Microbiology, Miami Beach, Fla, 1997, Abstract F-98.
72. Williams DM, Graybill JR, Drutz DJ: Histoplasma capsulatum infection in nude mice. Infect Immun 21:973-977, 1978.
73. Gomez AM, Bullock WE, Taylor CL, et al: The role of L3T4+ T cells in host defense against Histoplasma capsulatum. Infect Immun 56:1685-1689, 1988.
74. Deepe GS Jr: Role of CD8Ä+ T cells in host resistance to systemic infection with Histoplasma capsulatum in mice. J Immunol 152:3491-3500, 1994.
75. Deepe GS Jr: Protective immunity in murine histoplasmosis: Functional comparison of adoptively transferred T-cell clones and splenic T cells. Infect Immun 56:2350-2355, 1988.
76. Allendoerfer R, Magee DM, Deepe GS Jr, et al: Transfer of protective immunity in murine histoplasmosis by a CD4A+ T-cell clone. Infect Immun 61:714-718, 1993.
77. Wu-Hsieh B, Howard DH: Inhibition of growth of Histoplasma capsulatum by lymphokine-stimulated macrophages. /Immunol 132:2593-2597, 1984.
78. Deepe GS Jr, Smith JG, Sonnenfeld G, et al: Development and characterization of Histoplasma capsulatum-reactive murine T-cell clones. Infect Immun 54:714-722, 1986.
79. Wu-Hsieh BA, Howard DH: Inhibition of the intracellular growth of Histoplasma capsulatum by recombinant murine y Interferon. Infect Immun 55:1014-1016, 1987.
80. Chomarat P, Rissoan M-C, Banchereau J, et al: Interferon-/ inhibits interleukin 10 production by monocytes. ]Exp Med 177:523-527, 1993.
81. Seder RA, Paul WE: Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 12:635-674, 1994.
82. Saslow S, Schaeffer J: Survival of Histoplasma capsulatum in experimental histoplasmosis in mice. Proc Soc Exp Biol Med 91:412-414, 1956.
83. Medoff G, Sacco M, Maresca B, et al: Irreversible block of the mycelialto-yeast phase transition of Histoplasma capsulatum. Science 231:476-479, 1986.
84. Salvin SB: Constituents of the cell wall of the yeast phase of Histoplasma capsulatum. Am Rev Respir Dis 92:119-125, 1965.
85. Garcia JP, Howard DH: Characterization of antigens from the yeast phase of Histoplasma capsulatum. Infect Immun 4:116-125, 1976.
86. Feit C, Tewari RP: Immunogenicity of ribosomal preparations from yeast cells of Histoplasma capsulatum. Infect Immun 10:1091-1097, 1974.
87. Gomez AM, Rhodes JC, Deepe GS Jr: Antigenicity and immunogenicity of an extract from the cell wall and cell membrane of Histoplasma capsulation. Infect Immun 59:330-336, 1991.
88. Gomez FJ, Gomez AM, Deepe GS Jr: Protective efficacy of a 62 kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells. Infect Immun 59:4459-4464, 1991.
89. Gomez FJ, Allendoerfer R, Deepe GS Jr: Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis. Infect Immun 63:2587-2595,1995.
90. Fleischman J, Wu-Hsieh B, Howard DH: The intracellular fate of Histoplasma capsulatum in human macrophages is unaffected by recombinant human interferon-y. J Infect Dis 161:143-145, 1990.
91. Cesbron MF, Dubremetz JF, Sher A: 48th Forum in Immunology: Immunobiology of toxoplasmosis. Res Immunol 144:1-84, 1993.
92. Frenkel JK: Pathophysiology of toxoplasmosis. Parasitai Today 4:273-278, 1988.
93. Denkers EY, Gazzinelli RT: Regulation and function of T cell-mediated immunity during Toxoplasma gondii infection, din Microbiol Rev, in press.
94. Gazzinelli RT, Denkers EY, Sher A: Host resistance to Toxoplasma gondii: A model for studying the selective induction of cell-mediated immunity by intracellular parasites. Infect Agents Dis 2:139-149, 1993.
95. Scharton-Kerston T, Denkers EY, Gazzinelli RT, et al: Role of IL-12 in induction of cell-mediated immunity to Toxoplasma gondii. Res Immunol 146:539-546, 1995.
96. Biron CA, Gazzinelli RT: Effects of IL-12 on immune responses to microbial infections: A key mediator in regulating disease outcome. Curr Opin Immunol 7:485-496, 1995.
97. Sher A, Oswald IP, Hieny S, et al: Toxoplasma gondii induces a T-independent IFN-y response in natural killer cells that requires both adherent accessory cells and tumor necrosis factor-a. J Immunol 150:3982-3989, 1993.
98. Gazzinelli RT, Hieny S, Wynn T, et al: IL-12 is required for the T-cell independent induction of IFN- by an intracellular parasite and induces resistance in T-deficient hosts. Proc Natl Acad Sei USA 90:6115-6119, 1993.
99. Gazzinelli RT, Eltoum I, Wynn T, et al: Acute cerebral toxoplasmosis is induced by in vivo neutralization of TNF-a and correlates with down-regulated expression of inducible nitric oxide synthase and other markers of macrophage activation. J Immunol 151:3672-3681, 1993.
100. Gazzinelli RT, Bala S, Stevens R, et al: HIV infection suppresses Thl lymphokines and IL-12 responses to Toxoplasma gondii but fails to inhibit synthesis of other parasite induced monokines. J Immunol 155:1565-1574, 1995.
101. Grunvald E, Chiaramonte M, Hieny S: Biochemical characterization and protein kinase C dependency of monokine-inducing activities of Toxoplasma gondii. Infect Immun 64:2010-2018, 1996.
102. Gazzinelli RT, Morita Y, Hieny S, et al: Identification and isolation of adjuvant molecules from Toxoplasma gondii tachyzoites. Mem Inst Oswaldo Cruz 1997.
103. Gazzinelli RT, Camargo MM, Almeida IC, et al: Identification and characterization of protozoan products that trigger the synthesis of IL-12 by inflammatory macrophages. Chem Immunol 68:136-147, 1997.
104. Gazzinelli RT, Wysocka M, Hayashi S, et al: Parasite-induced IL-12 stimulates early IFN-7 synthesis and resistance during acute infection with Toxoplasma gondii. f Immunol 153:2533-2543, 1994.
105. Hunter CA, Abrams JS, Beaman MH, et al: Cytokine mRNA in the CNS of SCID mice infected with Toxoplasma gondii: Importance of T-cell independent regulation of resistance to T. gondii. Infect Immun 61:4038, 1993.
106. Hunter CA, Subauste CS, vanCleave VH, et al: Production of y Interferon by natural killer cells from Toxoplasma goncfä-infected SCID mice: Regulation by interleukin 10, interleukin 12 and tumor necrosis factor-a. Infect Immun 62:2818-2824, 1994.
107. Khan IA, Matsuura T, Kasper LH: Interleukin-12 enhances murine survival against acute toxoplasmosis. Infect Immun 62:1639-1642, 1994.
108. Souza CR, Hieny S, Scharton-Kersten T, et al: In vitro microbial stimulation induces rapid CD40L-independent production of IL-12 by dendritic cells and their re-distribution to T cell areas. J Exp Med 186:1819-1829, 1997.
109. Hunter CA, Chizzonite R, Remington JS: IL-lβ is required for IL-12 to induce production of IFN-y by NK cells. J Immunol 155:4347-4354, 1995.
110. Doherty TM, Seder RA, Sher A: Induction and regulation of IL-15 expression in murine macrophages. J Immunol 156:735-741, 1996.
111. Carson WE, Ross ME, Baiocchi RA, et al: Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-y by natural killer cells in vitro. J Clin Invest 96:2578-2582, 1995.
112. Miller MD, Krangel MS: Biology and biochemistry of the chemokines: A family of chemotactic and inflammatory cytokines. Crit Rev Immunol 12:17-46, 1992.
113. Johnson LL: A protective role for endogenous tumor necrosis factor in Toxoplasma gondii infection. Infect Immun 60:1979-1983, 1992.
114. Johnson LL, Gibson GW, Sayles PC: CR3-dependent resistance to acute Toxoplasma gondii infection in mice. Infect Immun 64:1998-2003, 1996.
115. Marth T, Kelsall BL: Regulation of interleukin-12 by complement receptor 3 signalling, f Exp Med 185:1987-1995, 1997.
116. Gazzinelli RT, Wysocka M, Hieny S, et al: In absence of endogenous IL-10 mice acutely infected with Toxoplasma gondii succumb to a le-thai immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-y, TNF-a. J Immunol 157:798, 1996.
117. Neyer LEG, Fort M, Remington JS, et al: Role of IL-10 on regulation of T-cell-dependent and T-cell-independent, mechanisms of resistance to Toxoplasma gondii. Infect Immun 65:1675-1682, 1997.
118. Hunter CA, Bermudez L, Beerking H, et al: Transforming growth factor-β inhibits interleukin-12-induced production of Interferon by natural killer cells: A role for transforming growth factor-β in the regulation of T cell-mediated resistance to Toxoplasma gondii. Eur J Immunol 25:994-1000, 1995.
119. Suzuki Y, Orellana MA, Schreiber RD, et al: Interferon-/: The major mediator of resistance against Toxoplasma gondii. Science 240:516-518, 1988.
120. Scharton-Kersten TM, Wynn TA, Denkers EY, et al: In the absence of endogenous IFN-y, mice develop unimpaired IL-12 responses to Toxoplasma gondii while failing to control acute infection. J Immunol 157:4045-4054, 1996.
121. Yap G, Scharton-Kersten T, Sher A: Double TNF-R KO are susceptible to Toxoplasma gondii infection. J Immunol, in press.
122. Scharton-Kersten T, Yap G, Sher A: Inducible nitric oxide synthase knockout mice are susceptible to chronic but not acute infection with avirulent strain of Toxoplasma gondii. J Exp Med 185:1261-1273, 1997.
123. Murray HW, Teitelbaum R: L-Arginine-dependent reactive nitrogen intermediates and the antimicrobial effect of activated human mononuclear phagocytes. J Infect Dis 165:513-517, 1992.
124. James S: Role of nitric oxide in parasitic infections. Microbiol Rev 59:533-547, 1995.
125. Nathan C, Nogueira N, Juangbhanich C, et al: Activation of macrophages: In vivo and in vitro correlation between hydrogen peroxide release and killing of Trypanosoma cruzi. J Exp Med 149:1056-1068, 1979.
126. Locksley RM, Klebanoff SJ: Oxygen-dependent microbicidal systems of phagocytes against intracellular protozoa. J Cell Biochem 22:173-185, 1983.
127. Locksley RM, Fankhauser J, Henderson WR: Alteration of leukotriene release by macrophages ingesting Toxoplasma gondii. Proc Natl Acad Sei USA 82:6922-6926, 1985.
128. Yong S, Lau S: Rapid separation of tryptophan, kinurenines, and indoles using reversed phase chromatography. J Chromatogr 175:343-348, 1995.
129. Murray HW, Szuro-Sudol A, Wellner D, et al: Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of -y interferon-stimulated human macrophages. Infect Immun 57:845-849, 1989.
130. Pfefferkorn ER: Interferon y blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sei USA 81:908-912, 1984.
131. Peterson PK, Gekker G, Hu S, et al: Human astrocytes inhibit intracellular multiplication of Toxoplasma gondii by a nitric oxide mediated mechanism. J Infect Dis 171:516-518, 1995.
132. Gazzinelli RT, Xu Y, Hieny S, et al: Simultaneous depletion of CD4+ and CD8+ T lymphocytes is required to reactivate chronic infection with Toxoplasma gondii. J Immunol 149:175-180, 1992.
133. Adams LB, Hibbs JB Jr, Taintor RR, et al: Microbiostatic effect of murine activated macrophages for Toxoplasma gondii. Role for synthesis of inorganic nitrogen oxides from L-arginine. J Immunol 144:2725-2729, 1990.
134. Sayles PC, Johnson LL: Exacerbation of toxoplasmosis in neutrophildepleted mice. Nat Immun 15:249-258, 1996.
135. Hunter CA, Candolfi CA, Subauste C, et al: Studies on the role of IL-12 in murine toxoplasmosis. Immunology 84:16-20, 1995.
136. Hunter CA, Neyer LE, Gabriel KE, et al: The role of the CD28/B7 interaction in regulation of NK cell responses during infection with Toxoplasma gondii. J Immunol 158:2285-2293, 1997.
137. Khatri VP, Fehniger TA, Baiocchi RA, et al: Ultra low dose IL-2 therapy promotes a type 1 cytokine profile in vitro in patients with AIDS and AIDS-associated malignancies. J Clin Invest 101:1373-1378, 1998.
138. Kasper LH, Matsuura T, Fonseka S, et al: Induction of 78 T cells during acute murine infection with Toxoplasma gondii. J Immunol 157:5521-5527, 1996.
139. dePaoli P, Basaglia G, Gennari D, et al: Phenotypic profile and functional characteristics of human y and 8 T cells during murine acute toxoplasmosis. J Clin Microbiol 30:729-731, 1992.
140. Nagasawa H, Oka M, Maedi KM, et al: Induction of heat shock protein closely correlates with protection against Toxoplasma infection. Proc Natl Acad Sei USA 89:3155-3158, 1992.
141. Subauste CS, Chung JY, Do D, et al: Preferential activation and expansion of human blood 78 T cells in response to Toxoplasma gondii in vitro and their cytokine production and cytotoxicity activity against T. gondii infected cells. J Clin Invest 96:610-619, 1995.
142. Perussia B, Chan SH, d'Andréa A, et al: Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-β, TCR-7 T lymphocytes, and NK cells. J Immunol 149:3495-3502, 1992.
143. Seder RA, Gazzinelli RT, Sher A, et al: IL-12 acts directly on CD4+ T cells to enhance priming for IFN-y production and diminishes IL-4 inhibition of such priming. Proc Natl Acad Sei USA 90:10188-10192, 1993.
144. Jacobson NG, Szabo SJ, Weber-Nordt RM, et al: Interleukin 12 signaling in T helper type 1 (Thl) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. J Exp Med 181:1755-1762, 1995.
145. LeGros G, Ben-Sasson SZ, Seder R, et al: Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J Exp Med 172:921-929, 1990.
146. Araujo FG: Depletion of L3T41 (CD4+) T lymphocytes prevents development of resistance to Toxoplasma gondii in mice. Infect Immun 59:1614-1619, 1991.
147. Brown CR, McLeod R: Class I MHC genes and CD8+ T cells determine cyst number in Toxoplasma gondii infection. J Immunol 145:3438-3441, 1990.
148. Scharton Kersten T, Nakajima T, Yap G, et al: Infection of mice lacking the common cytokine receptor- chain (gc) reveals an unexpected role for CD4+ T lymphocytes in early IFN-y dependent resistance to Toxoplasma gondii. J Immunol 160:2565-2569, 1998.
149. Navia BA, Petito CK, Gold JWM, et al: Cerebral toxoplasmosis complicating the acquired immune deficiency syndrome: Clinical and neuropathologic findings in 27 patients. Ann Neural 19:224-238, 1986.
150. Shearer GM, Bernstein DC, Tung KST, et al: A model for the selective loss of major histocompatibility complex self-restricted T cell immune responses during the development of acquired immune deficiency syndrome (AIDS), f Immunol 137:2514-2521, 1986.
151. Curiel TJ, Krug EC, Purner MB, et al: Cloned human CD4+ cytotoxic T lymphocytes specific for Toxoplasma gondii lyse tachyzoite-infected target cells. J Immunol 151:2024-2031, 1993.
152. Denkers E Y, Gazzinelli RT, Hieny S, et al: Bone marrow macrophages process exogenous Toxoplasma gondii polypeptides for recognition by parasite-specific cytolytic T lymphocytes. J Immunol 150:517-526, 1993.
153. Denkers EY, Yap G, Scharton-Kersten T, et al: Perforin-mediated cytolysis plays a limited role in host resistance to Toxoplasma gondii. J Immunol 159:1903-1908, 1997.
154. Waldeland H, Pfefferkorn ER, Frenkel JK: Temperature sensitive mutants of Toxoplasma gondii: Pathogenicity and persistence in mice. J Parasitai 69:171-175, 1983.
155. Gazzinelli RT, Hakim FT, Hieny S, et al: Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-y production and protective immunity induced by an attenuated Toxoplasma gondii vaccine. J Immunol 146:286-292, 1991.
156. Pfefferkorn ER, Pfefferkorn LC: Toxoplasma gondii: Isolation and preliminary characterization of temperature-sensitive mutants. Exp Parasitai 39:365-376, 1976.
157. Kasper LH, Currie KM, Bradley MS: An unexpected response to vaccination with a purified major membrane tachyzoite antigen (P30) of Toxoplasma gondii. J Immunol 134:3426-3431, 1985.
158. Yap GS, Scharton-Kersten T, Ferguson DJP, et al: Partially protective vaccination triggers latency in a normally virulent strain of Toxoplasma gondii. Infect Immun, in press.
159. Chang HR, Grau GE, Pechere JC: Role of TNF and IL-1 in infections with Toxoplasma gondii. Immunology 69:33-37, 1990.
160. Sharma SD, Hofflin JM, Remington JS: In vitro recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii. J Immunol 135:4160-4163, 1985.
161. Kasper LH, Matsuura T, Khan IA: IL-7 stimulates protective immunity in mice against the intracellular pathogen, Toxoplasma gondii. J Immunol 155:4798-4804, 1995.
162. + T cell mediated immunity against Toxoplasma gondii infection in mice. J Immunol 157:2103-2108, 1996.
163. Suzuki Y, Conley FK, Remington JS: Treatment of toxoplasmic encephalitis in mice with recombinant y Interferon. Infect Immun 58:3050-3055, 1990.